To Be Discontinued Injection Oncology
Docetaxel Injection · 444 days since initial FDA posting
Brand: DOCETAXEL
FDA lists Docetaxel Injection as To Be Discontinued (Pfizer Inc.).
No availability text on this FDA row.
Docetaxel Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Docetaxel Injection
- Manufacturer
- Pfizer Inc.
- Dosage Form
- Injection
- Presentation
- Docetaxel, Injection, 20 mg/2 mL (10 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial Novaplus® (NDC 0409-2026-01)
- Package NDC
- 0409-2026-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Jun 24, 2025
- Last Updated
- Jun 24, 2025
- Therapeutic Category
- Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Docetaxel Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.